#United States #New Haven #Biohaven Ltd. #David Pirman #Bruce Car

Biohaven Announces Transition in Scientific Leadership

Biohaven Ltd., a leading biopharmaceutical company focused on innovative therapies, has announced vital transitions within its scientific leadership team aimed at expediting drug development and fostering external collaborations. The company, listed on the NYSE under the ticker BHVN, made this significant announcement on July 9, 2026, outlining plans for enhancing its internal research capabilities and expanding strategic partnerships.

Key Leadership Changes

In a pivotal move, David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. Dr. Pirman will now oversee Biohaven's internal drug-discovery organization, managing various research initiatives aimed at developing groundbreaking treatments. His promotion reflects the company's faith in his leadership and significant contributions to the advancement of drug therapies within Biohaven’s portfolio.

Additionally, Bruce D. Car, DVM, Ph.D., DACVP, is transitioning from his role as Chief Scientific Officer to the newly established position of Chief Innovation Officer. Dr. Car will dedicate his efforts to advancing Biohaven's scientific initiatives, particularly through collaborations with external organizations. As part of this transition, Dr. Car will lead several projects in conjunction with Bexorg, Inc., a techbio company that specializes in next-generation therapies for central nervous system (CNS) disorders. Dr. Car's continued involvement, albeit in a part-time role, will ensure that he can impart insights and guidance while supporting the company's broad research objectives.

Warren Volles, the current General Counsel and Chief Legal Officer, has also been designated an executive officer, indicating Biohaven's emphasis on strong legal oversight as it pursues its ambitious innovation agenda.

Statements from Leadership

Vlad Coric, M.D., Chairman and CEO of Biohaven, expressed gratitude for Dr. Car’s substantial contributions in establishing Biohaven's scientific foundation. “Through Dr. Car's efforts, we have successfully translated discovery insights into a series of IND-stage programs that are critical to our pipeline,” he remarked. Coric also indicated that Dr. Pirman's elevation signifies both his leadership capabilities and Biohaven's ongoing commitment to scientific progress.

Dr. Bruce Car reassured stakeholders about the timing of his retirement, reflecting confidence in the existing research frameworks and leadership of Biohaven, and shared his excitement for the future trajectory of the company’s research.

Collaboration with Bexorg

Biohaven's recent collaboration with Bexorg, Inc., announced in June 2025, is structured to innovate therapeutic approaches for CNS disorders through comprehensive research methodologies. This collaboration leverages Bexorg’s exceptional whole-brain discovery platform, aimed at demonstrating target engagement in vital cell types and generating crucial biomarkers to bolster Biohaven's preclinical research initiatives. Through this strategic partnership, Biohaven is set to enhance its capabilities in designing therapeutic strategies tailored to complex neurological conditions.

About Biohaven

Biohaven Ltd. specializes in the discovery, development, and commercialization of life-altering treatments for patients suffering from debilitating illnesses. Their robust pipeline encompasses therapies targeting neuroscience, immunology, and various other medical domains. For further information on their innovative work, visit biohaven.com.

Conclusion

The recent transitions in Biohaven’s scientific leadership signal a renewed commitment to driving drug innovation and cultivating strategic partnerships. With seasoned professionals like Dr. Pirman and Dr. Car at the helm of these initiatives, the company is poised for a promising future in the pharmaceutical landscape, dedicated to addressing unmet medical needs through cutting-edge research and development.